Vitamin D3-driven signals for myeloid cell differentiation-Implications for differentiation therapy

Leukemia Research

Volumn 34, Issue 5, 2010, Pages 553-565

  Hughes, Philip J ^a   Marcinkowska, Ewa ^b   Gocek, Elzbieta ^b,c   Studzinski, George P ^c   Brown, Geoffrey ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF WROC AW   (Poland)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Cell signaling; Deltanoids; Differentiation therapy; Leukemia; Vitamin D3

Indexed keywords

22 OXACALCITRIOL; CCAAT ENHANCER BINDING PROTEIN BETA; CERAMIDE; JANUS KINASE; LIPID; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE A2; PHOSPHOLIPASE D; PROTEIN AKT 1; PROTEIN KINASE B BETA; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; RAF PROTEIN; RAS PROTEIN; RETINOBLASTOMA PROTEIN; SPHINGOMYELIN PHOSPHODIESTERASE; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; CALCITRIOL;

ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL STIMULATION; DOWN REGULATION; DRUG PROTEIN BINDING; ENZYME ACTIVATION; GENE TRANSLOCATION; GROWTH INHIBITION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; CYTOLOGY; DRUG EFFECT; MYELOID LEUKEMIA; PHYSIOLOGY; REVIEW; TUMOR CELL LINE;

CALCITRIOL; CELL DIFFERENTIATION; CELL LINE, TUMOR; HUMANS; LEUKEMIA, MYELOID; MYELOID CELLS; SIGNAL TRANSDUCTION;

EID: 77950088184     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.09.010     Document Type: Review

References (191)

1. 3. Proc Natl Acad Sci USA 1981, 78:4990-4994.
2. 3 induces differentiation of human myeloid leukaemia cells. Biochem Biophys Res Commun 1981, 102:937-942.
3. 3-induced differentiation in a human promyelocytic leukaemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells. J Cell Biol 1984, 98:391-398.
4. 3 co-operate to promote differentiation of the human promyeloid leukaemia cell line HL60 to monocytes. Leukemia 1994, 8:806-815.
5. 3 and retinoic acid in inducing U937 cell differentiation. J Nutr Sci Vitaminol (Tokyo) 1992, 38:415-426.
6. 3-induced myeloid cell differentiation is regulated by a vitamin D receptor-phosphatidylinositol 3-kinase signalling complex. J Exp Med 1999, 190:1583-1594.
7. Bar-Shavit Z., Kahn A.J., Stone K.R., Trial J., Hilliard T., Reitsma P.H., et al. Reversibility of vitamin D-induced leukaemia cell-line maturation. Endocrinology 1986, 118:679-686.
8. Studzinski G., Brelvi Z. Changes in proto-oncogene expression associated with reversal of macrophage-like differentiation of HL60 cells. J Natl Cancer Inst 1987, 79:67-76.
9. 3. Leuk Res 1997, 21:217-224.
10. Brown G., Choudhry M., Durham J., Drayson M., Michell R. Monocytically differentiating HL60 cells proliferate rapidly before they mature. Exp Cell Res 1999, 253:511-518.
11. Campbell M., Drayson M., Durham J., Wallington L., Siu-Caldera M., Reddy G., et al. Metabolism of and its 20-epi analog integrates clonal expansion, maturation and apoptosis during HL-60 cell differentiation. Mol Cell Endocrinol 1999, 149:169-183.
12. Lee Y., Galoforo S., Berns C., Blackburn R., Huberman E., Corry P. Dual effect of on hsp28 and PKCβ gene expression in phorbol ester-resistant human myeloid HL-525 leukemic cells. Biochem Pharmacol 1996, 52:311-319.
13. 3 analogue KH1060 and the phorbol ester TPA. Cancer Lett 2002, 186:67-74.
14. Marcinkowska E., Kutner A. Side chain modified vitamin D analogs require activation of both PI 3-K and erk1,2 signal transduction pathways to induce differentiation of human promyelocytic leukaemia cells. Acta Biochim Pol 2002, 49:393-406.
15. 3-stimulated increase in steroid sulphatase activity in myeloid leukaemic cell lines. J Cell Biochem 2008, 103:1551-1572.
16. 3 and participates in its anti-apoptotic effect and cell cycle control in differentiating HL60 cells. Cell Cycle 2006, 5:447-451.
17. 3-induced differentiation of HL60 cells. J Cell Biochem 2001, 80:471-482.
18. 3 activate three MAPK pathways and upregulate pRb expression in differentiating HL60 cells. Cell Cycle 2002, 1:410-415.
19. 3. Exp Cell Res 2006, 312:2054-2065.
20. Studzinski G., Garay E., Patel R., Zhang J., Wang X. Vitamin D receptor signalling of monocytic differentiation in human leukaemia cells: role of MAPK pathways in transcription factor activation. Curr Top Med Chem 2006, 6:1267-1271.
21. nuc-mediated activation of the RAS/RAF/ERK-MAP kinase signalling pathway. J Cell Biochem 2006, 98:590-617.
22. 3. J Cell Biochem 2003, 89:1087-1101.
23. 3-induced differentiation of HL60 cells but is not mediated by the MEK/ERK module. J Cell Physiol 2006, 209:253-260.
24. 3 receptor: a network of coactivator interactions. Gene 2000, 246:9-21.
25. Carlberg C., Dunlop T.W., Saramäki A., Sinkkonen L., Matilainen M., Väisänen S. Controlling the chromatin organization of vitamin D target genes by multiple vitamin D receptor binding sites. J Steroid Biochem Mol Biol 2007, 103:338-343.
26. 3 target genes. Mol Endocrinol 2005, 19:2685-2695.
27. Shah S., Islam M., Dakshanamurthy S., Rizvi I., Rao M., Herrell R., et al. The molecular basis of the vitamin D receptor and β-catenin crossregulation. Mol Cell 2006, 21:799-809.
28. 3 receptor. Blood 2001, 98:3290-3300.
29. O'Kelly J., Histake J., Histake Y., Bishop J., Norman A., Koeffler H.P. Normal myelopoiesis but abnormal T lymphocyte responses in vitamin D receptor knockout mice. J Clin Invest 2002, 109:1091-1099.
30. 3. Br J Haematol 1987, 67:267-271.
31. Hewison M., Dabrowski M., Vadher S., Faulkner L., Cockerill F.J., Brickell P., et al. Antisense inhibition of vitamin D receptor expression induces apoptosis in monoblastoid U937 cells. J Immunol 1996, 156:4391-4400.
32. Pramanik R., Asplin J., Lindeman C., Favus M., Bai S., Coe F. Lipopolysaccharide negatively modulates vitamin D action by down-regulating expression of vitamin D-induced VDR in human monocytic THP-1 cells. Cell Immunol 2004, 232:137-143.
33. 3 differentiation activity, hormone binding and hormone receptor expression in HL-60 human promyelocytic cells. Mol Cell Biochem 2000, 208:157-162.
34. 3 stimulates steroid sulphatase activity in HL60 and NB4 acute myeloid leukaemia cell lines by different receptor-mediated mechanisms. J Cell Biochem 2005, 94:1175-1189.
35. Prüfer K., Racz A., Lin G.C., Barsony J. Dimerization with retinoid X receptors promotes nuclear localization and subnuclear targeting of vitamin D receptors. J Biol Chem 2000, 275:41114-41123.
36. 3-26,23-lactone analogs antagonize differentiation of human leukemia cells (HL-60 cells) but not of human acute promyelocytic leukemia cells (NB4 cells). FEBS Lett 1999, 460:297-302.
37. 3-induced monocytic differentiation of HL60 cells. Cancer Res 2004, 64:370-377.
38. 3-26,23-lactam analogues function as vitamin D receptor antagonists in human and rodent cells. J Steroid Biochem Mol Biol 2008, 110:269-277.
39. 3, involves nuclear vitamin D receptor (nVDR) and non-nVDR-mediated pathways. J Cell Physiol 2002, 191:198-207.
40. Humeniuk-Polaczek R., Marcinkowska E. Impaired nuclear localization of vitamin D receptor in leukemia cells resistant to calcitriol-induced differentiation. J Steroid Biochem Mol Biol 2004, 88:361-366.
41. Wu-Wong J., Nakane M., Ma J., Dixon D., Gagne G. Vitamin D receptor (VDR) localization in human promyelocytic leukemia cells. Leuk Lymphoma 2006, 47:727-732.
42. 3-induced differentiation in human acute myeloid leukemia HL60-40AF cells is associated with reduced transcriptional activity and nuclear localization of the vitamin D receptor. J Cell Physiol 2007, 213:816-825.
43. Gocek E., Kiełbiński M., Marcinkowska E. Activation of intracellular signaling pathways is necessary for an increase in VDR expression and its nuclear translocation. FEBS Lett 2007, 581:1751-1757.
44. Gocek E., Kiełbiński M., Wyłób P., Kutner A., Marcinkowska E. Side-chain modified vitamin D analogs induce rapid accumulation of VDR in the cell nuclei proportionately to their differentiation-inducing potential. Steroids 2008, 73:1359-1366.
45. Nakano H., Matsunawa M., Yasui A., Adachi R., Kawana K., Shimomura I., et al. Enhancement of ligand dependent vitamin D receptor transactivation of the cardiotonic steroid bufalin. Biochem Pharmacol 2005, 70:1479-1486.
46. Amano Y., Cho Y., Matsunawa M., Komiyama K., Makishima M. Increased nuclear expression and transactivation of vitamin D receptor by the cardiotonic steroid bufalin in human myeloid leukemia cells. J Ster Biochem Mol Biol 2009, 114:144-151.
47. 3 receptor. Cancer Res 2002, 62:7050-7058.
48. Racanicchi S., Maccherani C., Liberatore C., Billi M., Gelmetti V., Panigada M., et al. Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells. EMBO J 2005, 24:1232-1242.
49. Mellor M., Parker P.J. The extended protein kinase C superfamily. Biochem J 1998, 332:281-292.
50. Tan S.I., Parker P.J. Emerging and diverse roles of protein kinase C in immune cell signalling. Biochem J 2003, 376:545-552.
51. Aihara H., Asaoka Y., Yoshida K., Nishizuka Y. Sustained activation of protein kinase C is essential to HL-60 cell differentiation to macrophage. Proc Natl Acad Sci USA 1991, 88:11062-11066.
52. Seibenhener M.L., Wooten M.W. Heterogeneity of protein kinase C isoform expression in chemically induced HL60 cells. Exp Cell Res 1993, 207:183-188.
53. Hooper W.C., Abraham R.T., Ashendel C.L., Woloschak G.E. Differential responsiveness to phorbol esters correlates with differential expression of protein kinase C in KG-1 and KG-1a human myeloid leukemia cells. Biochim Biophys Acta 1989, 1013:47-54.
54. Slapak C.A., Kharbanda S., Saleem A., Kufe D.W. Defective translocation of protein kinase C in multidrug-resistant HL-60 cells confers a reversible loss of phorbol ester-induced monocytic differentiation. J Biol Chem 1993, 268:12267-12273.
55. 3 in HL-60 cells. J Biol Chem 1990, 265:2370-2374.
56. 3-induced regulation of protein kinase C gene expression during HL-60 cell differentiation. Cell Growth Differ 1991, 2:187-194.
57. 3 regulation of protein kinase C levels and activity. Biochem Pharmacol 1997, 54:909-915.
58. 3-induced differentiation. J Biol Chem 1998, 273:19587-19591.
59. 3 primes acute promyelocytic cells for TPA-induced monocytic differentiation through both PKC and tyrosine phosphorylation cascades. Exp Cell Res 1996, 222:61-69.
60. 3 stimulates expression and translocation of protein kinase Cα and Cδ via a nongenomic mechanism and rapidly induces phosphorylation of a 33-kDa protein in acute promyelocytic NB4 cells. J Biol Chem 1996, 271:16090-16096.
61. Macfarlane D.E., Manzel L. Activation of β-isozyme of protein kinase C (PKC β) is necessary and sufficient for phorbol ester-induced differentiation of HL-60 promyelocytes. Studies with PKC β-defective PET mutant. J Biol Chem 1994, 269:4327-4331.
62. Kang S.N., Lee M.H., Kim K.M., Cho D., Kim T.S. Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by silibinin: involvement of protein kinase C. Biochem Pharmacol 2001, 61:1487-1495.
63. Kim S., Kim H., Kim T.S. Differential involvement of protein kinase C in human promyelocytic leukaemia cell differentiation enhanced by artemisinin. Eur J Pharmacol 2003, 482:67-76.
64. 3. J Cell Physiol 1997, 172:284-295.
65. 3 resting human peripheral blood mononuclear cells. Eur J Pharmacol 2008, 586:14-23.
66. Stone R.M., Weber B.L., Spriggs D.R., Kufe D.W. Phospholipase C activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood 1988, 72:739-744.
67. Barendsen N., Chen B. Phospholipase C-induced monocytic differentiation in a human monocytic leukemia cell line THP-1. Leuk Lymphoma 1992, 7:323-329.
68. Bertagnolo V., Marchisio M., Capitani S., Neri L.M. Intranuclear translocation of phospholipase Cβ2 during HL-60 myeloid differentiation. Biochem Biophys Res Commun 1997, 235:831-837.
69. Neri L.M., Bortul R., Borgatti P., Tabellini G., Baldini G., Capitani S., et al. Proliferating or differentiating stimuli act on different lipid-dependent signaling pathways in nuclei of human leukemia cells. Mol Biol Cell 2002, 13:947-964.
70. Cocco L., Faenza I., Follo M.Y., Ramazzotti G., Gaboardi G.C., Billi A.M., et al. Inositide signaling: Nuclear targets and involvement in myelodysplastic syndromes. Adv Enzyme Regul 2008, 48:2-9.
71. McDermot M., Wakelam M.J., Morris A.J., Phospholipase D. Biochem Cell Biol 2004, 82:225-253.
72. 2 activation. Biochem Biophys Res Commun 1999, 260:232-239.
73. Kang H.K., Lee H.Y., Lee Y.N., Jo E.J., Kim J.I., Kim G.Y., et al. Up-regulation of phospholipase Cγ1 and phospholipase D during the differentiation of human monocytes to dendritic cells. Int Immunopharmacol 2004, 4:911-920.
74. Lee T., Kim Y., Min do S., Park J., Kwon T. Se-methylselenocysteine enhances PMA-mediated CD11c expression via phospholipase D1 activation in U937 cells. Immunobiology 2006, 211:369-376.
75. El Marjou M., Montalescot V., Buzyn A., Geny B. Modifications in phospholipase D activity and isoform expression occur upon maturation and differentiation in vivo and in vitro in human myeloid cells. Leukemia 2000, 14:2118-2127.
76. Di Fulvio M., Gomez-Cambronero J. Phospholipase D (PLD) gene expression in human neutrophils and HL-60 differentiation. J Leukoc Biol 2005, 77:999-1007.
77. 3. Biochim Biophys Acta 1986, 877:423-432.
78. Honda A., Raz A., Needleman P. Induction of cyclo-oxygenase synthesis in human promyelocytic leukaemia (HL-60) cells during monocytic or granulocytic differentiation. Biochem J 1990, 272:259-262.
79. 3-induced HL-60 cells. Arch Biochem Biophys 2005, 436:32-39.
80. Bartke N., Hannun Y.A. Bioactive sphingolipids: metabolism and function. J Lipid Res 2009, 50:s91-s96.
81. 3-induced HL-60 cell differentiation. J Biol Chem 1994, 269:4070-4077.
82. 3-induced HL-60 cell differentiation. J Biol Chem 1990, 265:15823-15831.
83. 3 inhibits programmed cell death in HL-60 cells by activation of sphingosine kinase. Cancer Res 1998, 58:1817-1824.
84. 3 in HL-60 cells. Role in cell differentiation. J Biol Chem 1989, 264:19076-19080.
85. Langmann T., Buechler C., Ries S., Schaeffler A., Aslanidis C., Schuierer M., et al. Transcription factors Sp1 and AP-2 mediate induction of acid sphingomyelinase during monocytic differentiation. J Lipid Res 1999, 40:870-880.
86. 3-induced differentiation of human HL-60 leukemia cells. Life Sci 2007, 81:1638-1644.
87. Katso R., Okkenhaug K., Ahmadi K., White S., Timms J., Waterfield M.D. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001, 17:615-675.
88. Cantley C.W. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
89. Vanhaesebroeck B., Leevers S.J., Panayotou G., Waterfield M.D. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci 1997, 22:267-272.
90. Hawkins P.T., Anderson K.E., Davidson K., Stephens L.R. Signalling through class I PI3Ks in mammalian cells. Biochem Soc Trans 2006, 34:647-662.
91. Hanada M., Feng J., Hemmings B.A. Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochem Biophys Acta 2004, 1697:3-16.
92. Bozulic L., Hemmings B.A. PIKKing on PKB activity by phosphorylation. Curr Opin Cell Biol 2009, 21:256-261.
93. Bayascas J.R. Dissecting the role of the 3-phosphoinositide-dependent protein kinase-1 (PDK1) signalling pathways. Cell Cycle 2008, 7:2978-2982.
94. Haneline L.S., White H., Yang F.C., Chen C., Orschell C., Kapur R., et al. Genetic reduction of class IA PI-3 kinase activity alters fetal hematopoiesis and competitive repopulating ability of hematopoietic stem cells in vivo. Blood 2006, 107:1375-1382.
95. Bugarski D., Kristic A., Mojsilovic S., Vlaski M., Petakov M., Jovcic G., et al. Signalling pathways implicated in hematopoietic progenitor proliferation and differentiation. Exp Biol Med (Maywood) 2007, 232:156-163.
96. Lewis J.L., Marley S.B., Ojo M., Gordon M.Y. Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid progenitor cell proliferation and differentiation in vitro. Exp Hematol 2004, 32:36-44.
97. Pearn L., Fisher J., Burnett A.K., Darley R.L. The role of PKC and PDK1 in monocyte lineage specification by Ras. Blood 2007, 109:4461-4469.
98. Buitenhuis M., Verhagen L.P., van Deutekom H.W., Castor A., Verploegen S., Koenderman L., et al. Protein kinase B (c-akt) regulates hematopoietic lineage choice decisions during myelopoiesis. Blood 2008, 111:112-121.
99. S6K protein are involved in differentiation of HL-60 cells induced by calcitriol. Anticancer Res 1998, 18:3507-3514.
100. Pahl H.L., Scheibe R.J., Zhang D.E., Chen H.M., Galson D.L., Maki R.A., et al. The proto-oncogene PU.1 regulates expression of the myeloid-specific Cd11b promoter. J Biol Chem 1993, 268:5013-5020.
101. Chen H.M., Pahl H.L., Scheibe R.J., Zhang D.E., Tenen D.G. The Sp1 transcription factor binds the CD11b promoter specifically in myeloid cells in vivo and is essential for myeloid specific promoter activity. J Biol Chem 1993, 268:8230-8239.
102. Zhang D.E., Hetherington C.J., Tan S., Dziennis S.E., Gonzalez D.A., Chen H.M., et al. Sp1 is critical factor for the monocyte specific expression of human CD14. J Biol Chem 1994, 269:11425-11434.
103. Pan Z., Hetherington C.J., Zhang D.E. CCAAT/enhancer-binding protein activates the CD14 promoter and mediates transforming growth factor β signaling in monocyte development. J Biol Chem 1999, 274:23242-23248.
104. 3 differentially affect hematopoietic transcripton factors to induce monocytic differentiation. Int J Oncol 2007, 30:349-355.
105. Moeenrezakhanlou A., Nandan D., Reiner N.E. Identification of a calcitriol-regulated Sp-1 site in the promoter of human CD14 using a combined Western blotting electrophoresis mobility shift assay (WEMSA). Biol Proced Online 2008, 10:29-35.
106. 3. Oncogene 2004, 23:4856-4861.
107. kip1 by the VDR/Sp1 complex. J Cell Biochem 2006, 98:1450-1456.
108. skp2 expression via the Sp1 site in human prostate cancer cells. J Cell Physiol 2006, 209:363-369.
109. Moeenrezakhanlou A., Shephard L., Lam L., Reiner N.E. Myeloid cell differentiation in response to calcitriol for expression CD11b and CD14 is regulated by myeloid zinc finger-1 protein downstream of phosphatidylinositol 3-kinase. J Leukoc Biol 2008, 84:519-528.
110. Raman M., Chen W., Cobb M.H. Differential regulation and properties of MAPKs. Oncogene 2007, 26:3100-3131.
111. Dhillon A.S., Hagan S., Rath O., Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007, 26:3279-3290.
112. Ramos J.W. The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol 2008, 40:2707-2719.
113. Geest C.R., Coffer P.J. MAPK signaling pathways in the regulation of hematopoiesis. J Leukoc Biol 2009, 86:237-250. 10.1189/jlb.0209097.
114. Yen A., Roberson M.S., Varvayanis S. Retinoic acid selectively activates the ERK2 but not JNK/SAPK or p38 MAP kinases when inducing myeloid differentiation. In Vitro Cell Dev Biol Anim 1999, 35:527-532.
115. Zehorai E., Yao Z., Plotnikov A., Seger R. The subcellular localization of MEK and ERK-a novel nuclear traslocation signal (NTS) paves a way to the nucleus. Mol Cell Endocrinol 2009, 10.1016/j.mce.2009.04.008.
116. Kharbanda S., Saleem A., Emoto Y., Stone R., Rapp U., Kufe D. Activation of Raf-1 and mitogen-activated protein kinases during monocytic differentiation of human myeloid leukemia cells. Biol Chem 1994, 269:872-878.
117. 3 induced activation and subsequent nuclear translocation of MAPK is upstream regulated by PKC in HL-60 cells. Biochem Biophys Res Commun 1997, 241:419-426.
118. 3 in promyelocytic NB4 leukemia cells: a structure-function study. Endocrinology 1998, 139:457-465.
119. Wang X., Studzinski G.P. Phosphorylation of raf-1 by kinase suppressor of ras is inhibited by " MEK-specific" inhibitors PD 098059 and U0126 in differentiating HL60 cells. Exp Cell Res 2001, 268:294-300.
120. Davies S.P., Reddy H., Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000, 351:95-105.
121. Bain J., McLauchlan H., Elliott H., Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 2003, 371:199-204.
122. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007, 408:297-315.
123. 3-induced leukaemia cell function via Raf/Mek/Erk MAPK signaling. Eur J Cell Biol 2009, 88:103-115.
124. 3 involves Raf1 but not Erk 1/2 signaling. Cell Cycle 2008, 7:917-924.
125. Cieslik K., Zhu Y., Shtivelband M., Wu K. Inhibition of p90 ribosomal S6 kinase-mediated CCAAT/enhancer-binding protein β activation and cyclooxygenase-2 expression by salicylate. J Biol Chem 2005, 280:18411-18417.
126. Lee S.J., Kim S.G. Role of p90 ribosomal S6-kinase-1 in oltipraz-induced specific phosphorylation of CCAAT/enhancer binding protein-β for GSTA2 gene transactivation. Mol Pharmacol 2006, 69:385-396.
127. 3 in human leukemia HL60 cells through a vitamin D response element in the 5'-flanking region. Oncogene 2006, 25:7078-7085.
128. 3 and is required for optimal cell differentiation. Exp Cell Res 2007, 313:3034-3045.
129. Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 2005, 6:827-837.
130. McKay M.M., Ritt D.A., Morrison DK Signaling dynamics of the KSR1 scaffold complex. Proc Natl Acad Sci USA 2009, 106:11022-11027. 10.1073/pnas.0901590106.
131. Joneson T., Fulton J.A., Volle D.J., Chaika O.V., Bar-Sagi D., Lewis R.E. Kinase suppressor of Ras inhibits the activation of extracellular ligand-regulated (ERK) mitogen-activated protein (MAP) kinase by growth factors, activated Ras, and Ras effectors. J Biol Chem 1998, 273:7743-7748.
132. Kortum R.L., Lewis R.E. The molecular scaffold KSR1 regulates the proliferative and oncogenic potential of cells. Mol Cell Biol 2004, 24:4407-4416.
133. 3. J Cell Physiol 2004, 198:333-342.
134. Roux P.P., Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004, 68:320-344.
135. Krishna M., Narang H. The complexity of mitogen-activated kinases (MAPKs) made simple. Cell Mol Life Sci 2008, 65:3525-3544.
136. Hale K.K., Trollinger D., Rihanek M., Manthey C.L. Differential expression and activation of p38 mitogen-activated protein kinase α, β, γ, and δ in inflammatory cell lineages. J Immunol 1999, 162:4246-4252.
137. Uddin S., Ah-Kang J., Ulaszek J., Mahmud D., Wickrema A. Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells. Proc Natl Acad Sci USA 2004, 101:147-152.
138. Das S., Cho J., Lambertz I., Kelliher M.A., Eliopoulos A.G., Du K., et al. Tpl/Cot signals activate ERK, JNK and NF-kB in a cell type and stimulus dependent manner. J Biol Chem 2005, 280:23748-23757.
139. Shahjahan M., Dunphy C.H., Ewton Z., Zu Y., Monzon F.A., Rice L., et al. p38 mitogen-activated protein kinase has different degrees of activation in myeloproliferative disorders and myelodysplastic syndromes. Am J Clin Pathol 2008, 130:635-641.
140. Navas T.A., Mohindru M., Estes M., Ma J.Y., Sokol L., Pahanish P., et al. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood 2006, 108:4170-4177.
141. Zhou L., Opalinska J., Verma A. p38 MAP kinase regulates stem cell apoptosis in human hematopoietic failure. Cell Cycle 2007, 6:534-537.
142. Katsoulidis E., Li Y., Yoon P., Sassano A., Altman J., Kannan-Thulasiraman P., et al. Role of p38 mitogen activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes. Cancer Res 2005, 65:9029-9037.
143. 3-induced differentiation of human leukemia HL60 cells. Exp Cell Res 2000, 258:425-437.
144. Wang X., Studzinski G.P. Inhibition of p38MAP kinase potentiates the JNK/SAPK pathway and AP-1 activity in monocytic but not in macrophage or granulocytic differentiation of HL60 cells. J Cell Biochem 2001, 82:68-77.
145. Wang Q., Harrison J.S., Uskokovic M., Kutner A., Studzinski G.P. Translational study of vitamin D differentiation therapy of myeloid leukemia: effects of the combination with a p38 MAPK inhibitor and an antioxidant. Leukemia 2005, 19:1812-1817.
146. Valente R., Nascimento C., Araujo E., Rumjanek V. mCD14 expression in human monocytes is downregulated by ouabain via transactivation of epithelial growth factor receptor and activation of p38 mitogen-activated protein kinase. Neuroimmunomodulation 2009, 16:228-236.
147. Henklova P., Vrzal R., Papouskova B., Bednar P., Jancova P., Anzenbacherova E., et al. SB203580, a pharmacological inhibitor of p38 MAP kinase transduction pathway activates ERK and JNK MAP kinases in primary cultures of human hepatocytes. Eur J Pharmacol 2008, 593:16-23.
148. Karin M., Gallagher E. From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life 2005, 57:283-295.
149. Bode A., Dong Z. The functional contrariety of JNK. Molec Carcin 2007, 46:591-598.
150. Dhanasekara D., Reddy E. JNK signaling in apoptosis. Oncogene 2008, 27:6245-6251.
151. Chen-Deutsch Z., Garay E., Zhang J., Harrison J., Studzinski G.P. C-Jun-N-terminal kinase 2 (JNK2) antagonizes the signalling of differentiation by JNK1 in human myeloid leukaemia cells resistant to vitamin D. Leuk Res 2009, 33:1372-1378.
152. Dreskin S., Thomas G., Dale S., Heasley L. Isoforms of Jun kinase are differentially expressed and activated in human monocyte/macrophage (THP-1) cells. J Immunol 2001, 166:5646-5653.
153. 3. J Cell Biochem 2003, 89:1087-1110.
154. 3. Exp Cell Res 1996, 224:312-322.
155. Zhang J., Posner G.H., Danilenko M., Studzinski G.P. Differentiation-inducing potency of the seco-steroid JK-1624F2-2 can be increased by combination with an antioxidant and a p38MAPK inhibitor which upregulates the JNK pathway. J Steroid Biochem Mol Biol 2007, 105:140-149.
156. Lagos-Quintana M., Rauhut R., Lendeckel W., Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001, 294:853-858.
157. Lee R.C., Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001, 294:862-864.
158. Chen C.Z., Li L., Lodish H.F., Bartel D.P. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004, 303:83-86.
159. Fazi F., Rosa A., Fatica A., Gelmetti V., De Marchis M.L., Nervi C., et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPα regulates human granulopoiesis. Cell Cycle 2005, 123:819-831.
160. Shivdasani R.A. MicroRNAs: regulators of gene expression and cell differentiation. Blood 2006, 108:3646-3653.
161. Johnnidis J.B., Harris M.H., Wheeler R.T., Stehling-Sun S., Lam M.H., Kirak O., et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 2008, 451:1125-1129.
162. Fabbri M., Garzon R., Andreeff M., Kantarjian H.M., Garcia-Manero G., Calin G.A. MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia 2008, 22:1095-1105.
163. Mendell J.T. miRiad roles for the miR-17-92 cluster in development and disease. Cell 2008, 133:217-222.
164. 3. Cell Cycle 2009, 8:736-741.
165. Cuesta A., Martinez-Sanchez A., Gebauer G. miR181a regulates Cap-dependent translation of p27kip-1 mRNA in myeloid cells. Mol Cell Biol 2009, 29:2841-2851.
166. Garzon R., Pichiorri F., Palumbo T., Visentini M., Aqeilan R., Cimmino A., et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 2007, 26:4148-4157.
167. Debernardi S., Skoulakis S., Molloy G., Chaplin T., Dixon-McIver A., Young B.D. MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis. Leukemia 2007, 21:912-916.
168. 3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc Natl Acad Sci USA 1983, 80:201-204.
169. 3 prolongs survival time of leukemic mice. Proc Natl Acad Sci USA 1990, 87:3929-3932.
170. Metha A.B., Kumaran T.O., Marsh G.W., McCarthy D.M. Treatment of advanced myelodysplastic syndrome with alfacalcidol. Lancet 1984, 2:761.
171. 3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Reports 1985, 69:1399-1407.
172. 3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes. Am J Hematol 1991, 38:67-68.
173. Kelsey S., Newland A., Cuningham J., Makin H., Coldwell R., Mills M., et al. Sustained hematological response to high dose oral alfacalcidol in patients with myelodysplastic syndrome. Lancet 1992, 340:316-317.
174. Mellibovsky L., Diez A., Perez-Vila E., Serrano S., Nacher M., Aubia J. Vitamin D treatment in myelodysplastic syndromes. Br J Hematol 1998, 100:516-520.
175. 3 analogs: effect on leukemic clonal growth and differentiation, and on serum calcium levels. Leuk Res 1995, 19:65-72.
176. Brown A.J., Slatopolsky E. Vitamin D analogs: therapeutic applications and mechanisms for selectivity. Mol Aspects Med 2008, 29:433-452.
177. Vakirlis E., Kastanis A., Ioannides D. Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris. Ther Clin Risk Manag 2008, 4:141-148.
178. 2 (a novel, non-calcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. Cancer Res 2005, 65:2488-2497.
179. 2 analog (paricalcitol, zemplar) for treatment of myelodysplastic syndrome. Leuk Res 2005, 29:1259-1262.
180. 3 derivatives and rosemary preparations in a mouse model of myeloid leukemia. Int J Cancer 2006, 118:3012-3021.
181. 3 with two side chains: interaction with its nuclear receptor and cellular actions. J Med Chem 2000, 43:2719-2730.
182. 3 analogs have potent antitumor activity. J Steroid Biochem Molec Biol 2008, 112:151-156.
183. Shabtay A., Sharabani H., Barvish Z., Kafka M., Amichay D., Levy J., et al. Synergistic antileukemic activity of carnosic acid-rich rosemary extract and the 19-nor Gemini vitamin D analogue in a mouse model of systemic acute myeloid leukemia. Oncology 2008, 75:203-214.
184. Hamadani M., Awan FT Remission induction, consolidation and novel agents in development for adults with acute myeloid leukemia. Hematol Oncol 2009, 10.1002/hon.915.
185. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., et al. Pathology and genetics: tumours of haematopoietic and lymphoid tissues (World Health Organization classification of tumours) 2008, International Agency for Research on Cancer, p. 109-38. 7th ed.
186. Huang M.E., Ye Y.C., Chen S.R., Chai J.R., Lu J.X., Zhoa L., et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988, 72:567-572.
187. Sanz M.A., Grimwade D., Tallman M.S., Lowenberg B., Fenaux P., Estey E.H., et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009, 113:1875-1891.
188. 3. Br J Hematol 2001, 112:315-326.
189. 3-induced monocytic differentiation of HL-60 cells. Calcif Tissue Int 1996, 59:277-282.
190. Cohen S.B., Cheng T.T., Chindalore V., Damjanov N., Burgos-Vargas R., Delora P., et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009, 60:335-344.
191. Damjanov N., Kauffman R.S., Spencer-Green G.T. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009, 60:1232-1241.